Dentsply Sirona starts strategic review for Wellspect Healthcare unit

DENTSPLY SIRONA Inc.

Wellspect provides bladder/bowel care products (LoFric, Navina); $2B TAM.
Mid-to-high single-digit organic sales growth in 2023 and first 3Q of 2024.
Goldman Sachs & Co. LLC (financial) and Wachtell Lipton (legal) retained as advisors.
No deadline or assurance that a transaction will result from the review.
Q4 & full-year 2024 results to be reported on February 27, 2025 as planned.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.